Looking back and looking forward

This year Molecular Genetics & Genomic Medicine (MGGM) turns 5 years old. For the editors of this journal it is time for some reflection, “looking back and looking forward”. The first issue appeared in May of 2013, 60 years after the publication by Watson and Crick’s discovery of the double-helical structure of DNA and 10 years after the completion of the Human Genome Project.

The work for this journal began 1 year earlier with the selection of the Founding Editor-in-Chief (EIC) Max Muenke, choice of a journal title, and the Aims and Scope of the journal. Initial options for titles included Human & Medical Genetics, Medical Genetics & Genomic Medicine, and a few others, before Molecular Genetics & Genomic Medicine became the top choice. Suzanne Hart was chosen as Deputy Editor-in-Chief in part because of her expertise that is different from the EIC. Twenty-four colleagues (10 female and 14 male) with a wide range of expertise from 15 different countries were invited to serve on the MGGM Editorial Board.

The Aims and Scope of MGGM were and are broad, to encompass a wide range of topics including basic and translational science, technological advances, human and medical genetics, animal models of human disease, pharmacogenomics and translational medicine (Muenke, 2013). From the first Editorial to the Invited Commentaries in each issue, various aspects of genomic medicine have been illustrated: integration of genomic information into the delivery of health care (De Castro & Turner, 2017; Eng, 2013; Francke, 2013; Slavotinek, 2016; Solomon, 2016; Williams, 2015), educational opportunities (Hart & Hart, 2016; Korf, 2013; McCarthy, 2014; Muenke, 2016), genomic counseling (Middleton, Hall, & Patch, 2015; Ormond, 2013); diverse populations (Adeyemo & Rotimi, 2014), ethical considerations (Wilfond & Goddard, 2015; one of the 10 most highly cited articles in MGGM, see below), comparative genomics (Mullikin, 2014), and many more including specific groups of diseases: newborn screening (Levy, 2014); substance use disorders (Rutter & Volkow, 2014); hearing loss (Pandya, 2016); orofacial clefting (Adeyemo & Butali, 2017), and stuttering (Friere-Domingues & Drayna, 2017). Some of my personal (M.M.) highlights were those articles celebrating the sesquicentennial anniversary of Johann Gregor Mendel (De Castro, 2016; Opitz & Bianchi, 2015), including an essay by Mendel’s great-great-grandnephew, the Augustinian monk Father Clemens Richter (Richter, 2015).

Another regular feature of MGGM that started in 2014, the series on “Genetics and Genomic Medicine Around the World”, is certainly among our favorites. It was our hope that this series “will be an invaluable sounding board for learning how different countries and cultures view and adopt genetic and genomic testing” (Hart & Muenke, 2014). To date, this has been the longest running such series when compared to any other genetics journal. We have learned from two dozen countries: small (Cuba, Ecuador, Macedonia, Paraguay, Rwanda, Slovakia) and large (India,
Brazil, USA) and any size in between (Table 1; Figure 1). Working with colleagues around the world on these articles has been enjoyable and one of the most rewarding aspects of being the editors for MGGM.

Last, but not least, are the unsolicited, peer-reviewed articles. Many submissions come directly to MGGM, while others are referred from our many high-profile supporter journals published by Wiley, such as Human Mutation, Clinical Genetics, and American Journal of Medical Genetics (AJMG). As submissions have grown since 2013, the number of accepted articles has also steadily increased. Dedicated peer review and editorial evaluation ensures that all published articles meet rigorous scientific standards. As was our hope when the journal started, the topics of the unsolicited, peer-reviewed articles are broad, ranging from diagnosis to treatment as is well illustrated by the titles of the 10 most highly cited manuscripts (Table 2).

All MGGM articles are deposited in PubMed Central (PMC) and are indexed and discoverable in PubMed/MEDLINE. MGGM is now in Web of Science (WoS) via indexing in Clarivate Analytics’ Science Citation Index Expanded (SCIE).

In January 2017, the Founding Editor-in-Chief of MGGM became the third Editor-in-Chief of the American Journal of Medical Genetics Part A (AJMG) (Muenke, 2017). Moving forward, Max Muenke stepped down as EIC and Suzanne Hart is the Editor-in-Chief of MGGM starting with the January 2018 issue.

What has happened in the field of molecular genetics and genomic medicine over the past 5 years? Highlighted below is just a small selection of topics covered by review articles in the areas critical to our field: (1) technological advances leading to progress in (2) pharmacogenomics, (3) precision medicine in general, and (4) cancer genomics specifically.

Technological advances enabling better and cheaper next generation DNA sequencing (Goodwin, Mcpherson, & Mccombe, 2016; Shendure et al., 2017), including single cell genome sequencing (Gawad, Koh, & Quake, 2016), have made the less-than-$1,000 price tag per genome a reality. Despite the availability of tens of thousands of reference genomes such as ExAC (http://exac.broadinstitute.org), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar), and others (Tarailo-Graovac et al. 2017), high throughput functional validation of variants of unknown significance will continue to be critical in order to determine mechanisms of disease (zebrafish: Hong et al., 2016; mouse: Li et al., 2015; Liu et al., 2017; fruit fly: Zhu, Fu, Nettleton, Richman, & Han, 2017). Lastly, advances in genome engineering such as the CRISPER/Cas9 systems and others have led to breakthroughs in applications to gene therapy and regenerative medicine (Katreckar, Hu, & Mali, 2017).
Guidelines for the use of pharmacogenomics in clinical practice are available through the Clinical Pharmacogenetics Implementation Consortium (CPIC) (Johnson & Weitzen, 2016; Verbelen, Weale, & Lewis, 2017). To date, inherited variations in at least 20 genes have been shown to affect more than 80 medications and are actionable in the clinic (Relling & Evans, 2015). Noninvasive prenatal testing (NIPT) allows for prenatal pharmacogenomics, a “promising area of research” in the near future (Dorfman, Cheng, Hebert, Thummel, & Burke, 2016).

“The essential job of precision medicine is to match the right drugs to the right patients” (Letai, 2017). Precision medicine and cancer genomics specifically, have had numerous successes “from preconception to adult medicine” (Ashley, 2016; Rehm, 2017) from personalized treatment of cystic fibrosis to chronic myeloid leukemia and many others. Including diverse populations in human genomics research has become a priority for funding agencies like the National Institutes of Health in the US or the Wellcome Trust in the UK (Hindorff et al., 2018). Geographical differences in disease susceptibility have been recognized (Sud, Kinnersley, & Houlston, 2017; Tan, Mok, & Rebbeck, 2016). For example, prostate cancer has a higher incidence and more aggressive course in men of African descent compared to those from Northern Europe. Similarly, differences in incidence of lung cancer, colorectal cancer, and breast cancer have been identified in patients from different countries. Looking forward, we expect that with a decrease in price for medical genome sequencing and easier identification of disease-causing alleles, personalized pharmacogenomics and precision medicine will become a reality for many individuals over the next decade.

### Table 1: Genetics and genomic medicine around the world

| Region  | Country     | Authors and titles |
|---------|-------------|--------------------|
| Africa  | Egypt       | Temtamy and Hussen (2017) |
|         | Rwanda      | Uwineza and Mutesa (2015) |
|         | Mali        | Landour et al. (2016) |
|         | Morocco     | Belhassan, Ouldin, and Sefiani (2016) |
|         | Tunisia     | Elloumi and Chaabouni (2018) (in press) |
| Middle East | Saud Arabi | Alkurraya (2014) |
|         | Israel      | Zlotogora (2014) |
|         | Turkey      | Özelcilik (2017) |
| Europe  | Greece      | Manoli and Fryssira (2015) |
|         | Spain       | Pampols et al. (2016) |
|         | Slovakia    | Kádasi and Cisárk (2015) |
|         | Macedonia   | Sukarova-Angelovska and Petlichkovski (2018) (current issue) |
| Asia    | India       | Aggarwal and Phadke (2015) |
|         | Thailand    | Shotelerusk, Limwongse, and Mahasirimongkol (2014) |
|         | Indonesia   | Ariani, Soeharso, and Sjarif (2017) |
|         | Philippines | Padilla and Cutiongco-de la Paz (2016) |
| Americas| Cuba        | Balbuena and Teruel (2017) |
|         | Dominican Republic | Estrada-Veras, Cabrera- Peña, and Pérez-Estreella de Ferrán (2016) |
|         | Ecuador     | Paz-y-Miño, Sucoto, and Leone (2016) |
|         | Colombia    | De Castro and Restrepo (2015) |
|         | Brazil      | Passos-Bueno, Bertola, Horovitz, de Faria Ferraz, and Brito (2014) |
|         | Paraguay    | Ferreira and de Herreros (2014) |
|         | Chile       | Taucher (2015) |
|         | USA         | Ferreira, Regier, Hadley, Hart, and Muenke (2017); Regier, Ferreira, Hart, Hadley, and Muenke (2017) |

### Table 2: Top 10 most highly cited articles in MGGM (as of January 10, 2018)

| Times Cited | Authors and titles |
|-------------|--------------------|
| 26          | Hirotsu, Nakagomi, Sakamoto, Amemiya, Mochizuki, et al. (2015): Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing |
| 20          | Sofou et al. (2015): Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome |
| 19          | Hirotsu, Nakagomi, Sakamoto, Amemiya, Oyama, et al. (2015): Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer |
| 18          | Yang et al. (2015): Taurodontism, variations in tooth number, and misshapened crowns in Wnt10a null mice and human kindreds |
| 17          | Sekulic et al. (2015): Personalized treatment of Sezary syndrome by targeting a novel CTLA4: CD28 fusion |
| 11          | De Kovel et al. (2016): Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients |
| 11          | Yigit et al. (2015): Mutations in CDK5RAP2 cause Seckel syndrome |
| 10          | Kassab et al. (2016): GATA5 mutation homozygosity linked to a double outlet right ventricle phenotype in a Lebanese patient |
| 10          | Wilfond and Goddard (2015): It’s complicated: criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making |
| 10          | Ammar-Khodja et al. (2015): Diversity of the causal genes in hearing impaired Algerian individuals identified by whole exome sequencing |
Looking back has been inspiring, but looking forward is exciting! If the past five years are any indication of the rapid pace of future research, then the next five years in the allied fields of molecular genetics and genomic medicine will be full of new discoveries that will facilitate an improved understanding of the genetic etiology of disease. Such discoveries could in turn provide tools for better patient understanding and disease prevention, or stimulate investment in applied research that might speed the delivery of targeted treatments to the patient bedside. It is within this exciting research environment that the journal *Molecular Genetics & Genomic Medicine* proudly finds its home. Our journal’s Open Access publication policy fully supports the public sharing of scientific knowledge aimed at advancing these admirable goals. As the editors of *MGGM*, we are honored to be able to publish, and make publicly available, papers representing the widest possible range of human and medical genetics research, and to provide valuable commentaries and global insights on new research and treatment trends. We sincerely thank the Editorial Board, our esteemed peer reviewers, and most of all, the authors and readers of *MGGM* for this honor.

So, at the start of 2018, we are proud of the accomplishments of *MGGM* over the past five years and are looking forward to continuing to publish high quality articles in the field in both the *American Journal of Medical Genetics* and *Molecular Genetics & Genomic Medicine*. We wish our readers the very best in 2018.

Max and Suzanne

Maximilian Muenke, Founding Editor-in-Chief
Suzanne Hart, Editor-in-Chief

*National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA*

**Correspondence**
Maximilian Muenke, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Email: max.muenke@mggmjournal.com

Drs. Muenke and Hart wrote this Editorial in their personal capacity and not as part of their official duties.

**REFERENCES**

Adeyemo, W. L., & Butali, A. (2017). Genetics and genomics etiology of nonsyndromic orofacial clefts. *Molecular Genetics & Genomic Medicine, 53*, 3–7. https://doi.org/10.1002/mgg3.272

Adeyemo, A., & Rotimi, C. (2014). What does genomic medicine mean for diverse populations? *Molecular Genetics & Genomic Medicine, 2*, 3–6. https://doi.org/10.1002/mgg3.63

Aggarwal, S. S., & Phadke, S. R. (2015). Medical genetics and genomic medicine in India: Current status and opportunities ahead. *Molecular Genetics & Genomic Medicine, 3*, 160–171. https://doi.org/10.1002/mgg3.150

Alkuraya, F. S. (2014). Genetics and genomic medicine in Saudi Arabia. *Molecular Genetics & Genomic Medicine, 2*, 369–378. https://doi.org/10.1002/mgg3.97

Ammar-Khodja, F., Bonnet, C., Dahmani, M., Ouhab, S., Lefèvre, G. M., Ibrahim, H., … Petit, C. (2015). Diversity of the causal genes in hearing impaired Algerian individuals identified by whole exome sequencing. *Molecular Genetics & Genomic Medicine, 3*, 189–196. https://doi.org/10.1002/mgg3.131

Ariani, Y., Soeharso, P., & Sjarif, D. R. (2017). Genetics and genomic medicine in Indonesia. *Molecular Genetics & Genomic Medicine, 5*, 103–109. https://doi.org/10.1002/mgg3.284

Ashley, E. A. (2016). Towards precision medicine. *Nature Reviews Genetics, 17*, 507–522. https://doi.org/10.1038/nrg.2016.86

Balbuena, H. R., & Teruel, B. M. (2017). Genetics and genomic medicine in Cuba. *Molecular Genetics & Genomic Medicine, 5*, 196–201. https://doi.org/10.1002/mgg3.299

Belhassan, K., Ouldlim, K., & Sefiani, A. A. (2016). Genetic and genomic medicine in Morocco: The present hope can make the future bright. *Molecular Genetics & Genomic Medicine, 4*, 588–598. https://doi.org/10.1002/mgg3.255

De Castro, M. (2016). Johann Gregor Mendel: Paragon of experimental science. *Molecular Genetics & Genomic Medicine, 4*, 3–8. https://doi.org/10.1002/mgg3.199

De Castro, M., & Restrepo, C. M. (2015). Genetics and genomic medicine in Colombia. *Molecular Genetics & Genomic Medicine, 3*, 84–91. https://doi.org/10.1002/mgg3.139

De Castro, M. J., & Turner, C. E. (2017). Military genomics: A perspective on the successes and the challenges of genomic medicine in the Armed Forces. *Molecular Genetics & Genomic Medicine, 5*, 617–620. https://doi.org/10.1002/mgg3.335

De Kovel, C. G. F., Brilstra, E. H., van Kempen, M. J. A., van’t Slot, R., Nijman, I. J., Afawi, Z., … Helbig, I. (2016). Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients. *Molecular Genetics & Genomic Medicine, 4*, 568–580. https://doi.org/10.1002/mgg3.235

Dorfman, E. H., Cheng, E. Y., Hebert, M. F., Thummel, K. E., & Burke, W. (2016). Prenatal pharmacogenomics: A promising area for research. *Pharmacogenomics Journal, 16*, 303–304. https://doi.org/10.1038/tpj.2016.33

Elloumi, H., & Chaabouni, H. (2018). Genetics and genomic medicine in Tunisia. *Molecular Genetics & Genomic Medicine, (in press).*

Eng, C. (2013). Molecular genetics to genomic medicine practice: At the heart of value-based delivery of healthcare. *Molecular Genetics & Genomic Medicine, 1*, 189–193.

Estrada-Veras, J. I., Cabrera-Peña, G. A., & Pérez-Estrella de Ferrán, C. (2016). Molecular genetics and genomic medicine in the Dominican Republic: Challenges and opportunities. *Molecular Genetics & Genomic Medicine, 4*, 243–256. https://doi.org/10.1002/mgg3.224

Ferreira, C. R., & de Herreros, M. B. (2014). Medical genetics in Paraguay. *Molecular Genetics & Genomic Medicine, 2*, 458–466. https://doi.org/10.1002/mgg3.119

Ferreira, C. R., Regier, D. S., Hadley, D. W., Hart, P. S., & Muenke, M. (2017). Medical genetics and genomic medicine in the United States of America. Part 1: History, demographics, legislation, and
Francke, U. (2013). How will genomic information become integrated into the health care system? *Molecular Genetics & Genomic Medicine, 1*, 67–70. https://doi.org/10.1002/mgg3.26

Frierio-Domingues, C., & Drayna, D. (2017). Genetic contributions to stuttering: The current evidence. *Molecular Genetics & Genomic Medicine, 5*, 95–102. https://doi.org/10.1002/mgg3.276

Gawad, C., Koh, W., & Quake, S. R. (2016). Single-cell genome sequencing: Current state of the science. *Nature Reviews Genetics, 17*, 175–188. https://doi.org/10.1038/nrg.2015.16

Goodwin, S., Mcpherson, J. D., & Mccombe, W. R. (2016). Coming of age: Ten years of next-generation sequencing technologies. *Nature Reviews Genetics, 17*, 333–351. https://doi.org/10.1038/nrg.2016.49

Hart, P. S., & Hart, T. C. (2016). The need for human genetics and genomics in dental school curricula. *Molecular Genetics & Genomic Medicine, 4*, 123–125. https://doi.org/10.1002/mgg3.216

Hart, P. S., & Muenke, M. (2014). Genetics and genomic medicine around the world. *Molecular Genetics & Genomic Medicine, 2*, 1–2. https://doi.org/10.1002/mgg3.59

Hindorff, L. A., Bonham, V. L., Brody, L. C., Ginoza, M. E. C., Hut- ter, C. M., Manolio, T. A., & Green, E. D. (2018). Prioritizing diversity in human genomics research. *Nature Reviews Genetics, (Epub ahead of print).*

Hirotu, Y., Nakagomi, H., Sakamoto, I., Amemiya, K., Mochizuki, H., & Omata, M. (2015). Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. *Molecular Genetics & Genomic Medicine, 3*, 121–129. https://doi.org/10.1002/mgg3.120

Hirotu, Y., Nakagomi, H., Sakamoto, I., Amemiya, K., Oyama, T., Mochizuki, H., & Omata, M. (2015). Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. *Molecular Genetics & Genomic Medicine, 3*, 459–466.

Hong, S., Hu, P., Marino, J., Hufnagel, S. B., Hopkin, R. J., Toromanovic, A., … Muenke, M. (2016). Dominant-negative kinase domain mutations in FGFR1 can explain the clinical severity of Hartsfield syndrome. *Human Molecular Genetics, 25*, 1912–1922.

Johnson, J., & Weitzel, K. (2016). Advancing pharmacogenomics as a component of precision medicine: How, where, and who? *Clinical Pharmacology & Therapeutics, 99*, 154–156.

Kaidas, L., & Cisárik, F. (2015). Genetics and genomics in Slovakia. *Molecular Genetics & Genomic Medicine, 3*, 8–13.

Kassab, K., Hairi, H., Gharibeh, L., Fahed, A. C., Zein, M., El-Rassy, I., … Nemer, G. (2016). GATA5 mutation homozygosity linked to a double outlet right ventricle phenotype in a Lebanese patient. *Molecular Genetics & Genomic Medicine, 4*, 160–171.

Katerek, D., Hu, M., & Mali, P. (2017). Advances in CRISPR-Cas based genome engineering. *Current Opinion in Biomedical Engineering, 1*, 78–86.

Korf, B. R. (2013). Genomic medicine: Educational challenges. *Molecular Genetics & Genomic Medicine, 1*, 119–122.

Landoué, G., Samassekou, O., Traoré, M., Meilleur, K. G., Guinto, C. O., Burnett, B. G., Fischbeck, K. H. (2016). Genetics and genomic medicine in Mali: Challenges and future perspectives. *Molecular Genetics & Genomic Medicine, 4*, 126–134.

Letai, A. (2017). Functional precision cancer medicine—moving beyond pure genomics. *Nature Medicine, 23*, 1028–1035.

Levy, H. L. (2014). Newborn screening: The genomic challenge. *Molecular Genetics & Genomic Medicine, 2*, 81–84.

Li, Y., Klena, N. T., Gabriel, G. C., Liu, X., Kim, A. J., Lemke, K., … Chang, C. (2015). Global genetic analysis in mice unveils central role for cilia in congenital heart disease. *Nature, 521*, 520–524.

Liu, X., Yagi, H., Saeed, S., Bais, A. S., Gabriel, G. C., Chen, Z., … Saydmohammed, M. (2017). The complex genetics of hypoplastic left heart syndrome. *Nature Genetics, 49*, 1152–1159. https://doi.org/10.1038/ng.3870

Manoli, I., & Fryssira, H. (2015). Medical genetics and genomic medicine in Greece: Achievements and challenges. *Molecular Genetics & Genomic Medicine, 3*, 383–390.

McCarthy, J. J. (2014). Driving personalized medicine forward: The who, what, when, and how of educating the health-care workforce. *Molecular Genetics & Genomic Medicine, 2*, 455–457.

Middleton, A., Hall, G., & Patch, C. (2015). Genetic counselors and genomic counseling in the United Kingdom. *Molecular Genetics & Genomic Medicine, 3*, 79–83.

Muenke, M. (2013). Individualized genomics and the future of translational medicine. *Molecular Genetics & Genomic Medicine, 1*, 1–3.

Muenke, M. (2016). Mentors without borders. *Molecular Genetics & Genomic Medicine, 4*, 489–493.

Muenke, M. (2017). Standing on the shoulders of giants. *American Journal of Medical Genetics, 173A*, 13–15.

Mullikin, J. C. (2014). The evolution of comparative genomics. *Molecular Genetics & Genomic Medicine, 2*, 363–368.

Opitz, J. M., & Bianchi, D. W. (2015). Mendel: Morphologist and mathematician founder of genetics – to begin a celebration of the 2015 sesquicentennial of Mendel’s presentation in 1865 of his Versuche über Pflanzenhybriden. *Molecular Genetics & Genomic Medicine, 3*, 1–7.

Ormond, K. E. (2013). From genetic counseling to “genomic counsel- ing”. *Molecular Genetics & Genomic Medicine, 1*, 189–1933.

Özçelik, T. (2017). Medical genetics and genomic medicine in Turkey: A bright future at a new era in life sciences. *Molecular Genetics & Genomic Medicine, 5*, 466–472.

Padilla, C. D., & Cutiongco-de la Paz, E. M. (2016). Genetics and genomic medicine in the Philippines. *Molecular Genetics & Genomic Medicine, 4*, 493–503.

Pämpols, T., Ramos, F. J., Lapunzina, P., Gozalo-Salellas, I., P€€Versuche, P., …, T., Ramos, F. J., Lapunzina, P., Gozalo-Salellas, I., P€€Versuche, P., … (2017). Molecular Genetics & Genomic Medicine, 2, 121. – 126.

Papas, M., Berto, O., Horovitz, D. G., de Faria Ferraz, V. M., & Omata, M. (2015). Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. *Molecular Genetics & Genomic Medicine, 3*, 121–129. https://doi.org/10.1002/mgg3.120

Regier, D. S., Ferreira, C. R., Hart, S., Hadley, D. W., & Muenke, M. (2017). Medical genetics and genomic medicine in the United States. Part 2: Reproductive genetics, newborn screening, genetic counseling, training, and registries. *Molecular Genetics & Genomic Medicine, 5*, 521–630. https://doi.org/10.1002/mgg3.343

Rehm, H. L. (2017). Evolving health care through personal genomics. *Nature Reviews Genetics, 18*, 259–267.
Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. Nature, 526, 343–350.

Richter, C. (2015). Remembering Johann Gregor Mendel: A human, a Catholic priest, an Augustinian monk, and abbot. Molecular Genetics & Genomic Medicine, 3, 483–485.

Rutter, J. L., & Volkow, N. D. (2014). Re-definingG AddiCCH3Tion: Genomics and epigenomics on substance use disorder. Molecular Genetics & Genomic Medicine, 2, 273–279.

Sekulic, A. W. S., Liang, W., Tembe, T., Izatt, S., Kruglyak, S., Kiefer, J. A., ... Gohmann, J. J. (2015). Personalized treatment of Sezary syndrome by targeting a novel CTLA4: CD28 fusion. Molecular Genetics & Genomic Medicine, 3, 130–136.

Shendure, J., Balasubramanian, S., Church, G. M., Gilbert, W., Rogers, J., Schloss, J. A., & Waterston, R. H. (2017). DNA sequencing at 40: Past, present and future. Nature, 550, 345–353. https://doi.org/10.1038/nature24286

Shotelersuk, V., Limwongse, C., & Mahasirimongkol, S. (2014). Personalized treatment of Sezary syndrome by targeting a novel CTLA4: CD28 fusion. Molecular Genetics & Genomic Medicine, 2, 210–216.

Slavotinek, A. (2016). Clinical care in the era of next-generation sequencing. Molecular Genetics & Genomic Medicine, 4, 239–242.

Sofou, K., Kollberg, G., Holmström, M., Davila, M., Darin, N., Gustafsson, C. M., ... Asin-Cayuela, J. (2015). Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome. Molecular Genetics & Genomic Medicine, 3, 59–68.

Solomon, B. D. (2016). Obstacles and opportunities for the future of genomic medicine. Molecular Genetics & Genomic Medicine, 2, 205–209.

Sud, A., Kinnersley, B., & Houlston, R. S. (2017). Genome-wide association studies of cancer: Current insights and future perspectives. Nature Reviews Cancer, 17, 692–704.

Sukarova-Angelovska, E., & Petlichkovski, A. (2018). Genetics in Macedonia – following the international trends. Molecular Genetics & Genomic Medicine, 6, 9–14.

Tan, D. S., Mok, T. S., & Rebbeck, T. R. (2016). Cancer genomics: Diversity and disparity across ethnicity and geography. Journal of Clinical Oncology, 34, 91–101.

Taran-Graovac, M., Zhu, J. Y. A., Matthews, A., van Karnebeek, C. D. M., & Wasserman, W. W. (2017). Assessment of the ExAC data set for the presence of individuals with pathogenic genotypes implicated in severe Mendelian pediatric disorders. Genetics in Medicine, 19, 1300–1308.

Taucher, S. C. (2015). Medical genetics in Chile: Opportunities for improvement. Molecular Genetics & Genomic Medicine, 3, 243–247.

Tentamy, S. A., & Hussen, D. F. (2017). Genetics and genomic medicine in Egypt: Steady pace. Molecular Genetics & Genomic Medicine, 5, 8–14.

Uwineza, A., & Mutesa, L. (2015). Genetics and genomic medicine in Rwanda. Molecular Genetics & Genomic Medicine, 3, 486–489.

Verbelen, M., Weale, M. E., & Lewis, C. M. (2017). Cost-effectiveness of pharmacogenetic-guided treatment: Are we there yet? Pharmacogenomics Journal, 17, 395–402.

Wilford, B. S., & Goddard, K. A. B. (2015). It’s complicated: Criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making. Molecular Genetics & Genomic Medicine, 3, 239–242.

Williams, M. S. (2015). Perspectives on what is needed to implement genomic medicine. Molecular Genetics & Genomic Medicine, 3, 155–159.

Yang, J., Wang, S. K., Choi, M., Reid, B. M., Hu, Y., Lee, Y. L., ... Kent Lloyd, K. C. (2015). Taurodontism, variations in tooth number, and misshapen crowns in Wnt10a null mice and human kindreds. Molecular Genetics & Genomic Medicine, 3, 40–58.

Yigit, G., Brown, K. E., Kayserili, H., Pohl, E., Calibe, A., Zahnleiter, D., ... Nürnberg, G. (2015). Mutations in CDK5RAP2 cause Seckel syndrome. Molecular Genetics & Genomic Medicine, 3, 467–480.

Zhu, J., Fu, Y., Nettleton, M., Richman, A., & Han, Z. (2017). High throughput in vivo functional validation of candidate congenital heart disease genes in Drosophila. eLife, 6, e22617.

Zlotogora, J. (2014). Genetics and genomic medicine in Israel. Molecular Genetics & Genomic Medicine, 2, 85–94.